Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 3
1991 12
1992 21
1993 18
1994 40
1995 41
1996 52
1997 71
1998 99
1999 94
2000 69
2001 86
2002 112
2003 81
2004 83
2005 100
2006 111
2007 110
2008 102
2009 107
2010 131
2011 104
2012 88
2013 115
2014 101
2015 103
2016 129
2017 111
2018 95
2019 102
2020 100
2021 95
2022 74
2023 71
2024 55
2025 47

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,673 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for advair j
Search for Advait J instead (1 results)
Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Free article. Clinical Trial.
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone group. Indacaterol-glycopyrronium showed not only noninferiority but also superiority to salmeterol-fluticasone in reducing …
RESULTS: A total of 1680 patients were assigned to the indacaterol-glycopyrronium group, and 1682 to the salmeterol-fluticasone …
Comparative Effectiveness and Safety of Generic Versus Brand-Name Fluticasone-Salmeterol to Treat Chronic Obstructive Pulmonary Disease.
Feldman WB, Kesselheim AS, Avorn J, Russo M, Wang SV. Feldman WB, et al. Ann Intern Med. 2023 Aug;176(8):1047-1056. doi: 10.7326/M23-0615. Epub 2023 Aug 8. Ann Intern Med. 2023. PMID: 37549393 Free PMC article. Clinical Trial.
The inhaler, Wixela Inhub (fluticasone-salmeterol; Viatris), is a substitutable version of the dry powder inhaler Advair Diskus (fluticasone-salmeterol; GlaxoSmithKline). ...OBJECTIVE: To compare the effectiveness and safety of generic (Wixela I …
The inhaler, Wixela Inhub (fluticasone-salmeterol; Viatris), is a substitutable version of the dry powder inhaler Advair …
Advair: combination treatment with fluticasone propionate/salmeterol in the treatment of asthma.
Nelson HS. Nelson HS. J Allergy Clin Immunol. 2001 Feb;107(2):398-416. doi: 10.1067/mai.2001.112939. J Allergy Clin Immunol. 2001. PMID: 11174215 Review.
In cases of moderate-to-severe persistent asthma, the addition of a second long-term control medication to ICS therapy is one recommended treatment option. A combination-product inhaler (Advair, Seretide) was developed to treat both the inflammatory and bronchoconst …
In cases of moderate-to-severe persistent asthma, the addition of a second long-term control medication to ICS therapy is one recommended tr …
Salmeterol-Fluticasone: The Role Revisited.
Vora A, Dhar R, Pinto L, Koul P, Gaonkar P. Vora A, et al. J Assoc Physicians India. 2022 Dec;69(12):11-12. J Assoc Physicians India. 2022. PMID: 35057598
Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatment with a combination of inhaled corticosteroids (ICS)/ long-acting beta-agonists (LABA); several studies have shown improvement in t …
Evidence of eosinophilia (marker of inflammation) in patients with asthma, asthma COPD overlap phenotype or COPD alone should prompt treatme …
Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.
Chapman KR, Hurst JR, Frent SM, Larbig M, Fogel R, Guerin T, Banerji D, Patalano F, Goyal P, Pfister P, Kostikas K, Wedzicha JA. Chapman KR, et al. Am J Respir Crit Care Med. 2018 Aug 1;198(3):329-339. doi: 10.1164/rccm.201803-0405OC. Am J Respir Crit Care Med. 2018. PMID: 29779416 Free article. Clinical Trial.
METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/glycopyrronium (110/50 mug once daily) or continuation of triple therapy (tiotropium [18 mug] once daily plus combination of salme …
METHODS: This 26-week, randomized, double-blind, triple-dummy study assessed the direct change from long-term triple therapy to indacaterol/ …
Stepping down therapy in COPD.
Reilly JJ. Reilly JJ. N Engl J Med. 2014 Oct 2;371(14):1340-1. doi: 10.1056/NEJMe1409219. Epub 2014 Sep 8. N Engl J Med. 2014. PMID: 25196116 No abstract available.
Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma.
Ng D, Kerwin EM, White MV, Miller SD, Haughie S, Ward JK, Allan R. Ng D, et al. J Aerosol Med Pulm Drug Deliv. 2020 Apr;33(2):99-107. doi: 10.1089/jamp.2019.1547. Epub 2019 Oct 31. J Aerosol Med Pulm Drug Deliv. 2020. PMID: 31634023 Free PMC article. Clinical Trial.
Background: Wixela() Inhub() is a dry powder inhaler approved as a generic equivalent to Advair() Diskus() (fluticasone propionate [FP]/salmeterol fixed-dose combination) for patients with asthma or chronic obstructive pulmonary disease (COPD). This st …
Background: Wixela() Inhub() is a dry powder inhaler approved as a generic equivalent to Advair() Diskus() (fluticasone propio …
Choosing asthma step-up care.
von Mutius E, Drazen JM. von Mutius E, et al. N Engl J Med. 2010 Mar 18;362(11):1042-3. doi: 10.1056/NEJMe1002058. Epub 2010 Mar 2. N Engl J Med. 2010. PMID: 20197426 No abstract available.
Pharmacokinetic Models for Inhaled Fluticasone Propionate and Salmeterol Xinafoate to Quantify Batch-to-Batch Variability.
Li S, Feng K, Lee J, Gong Y, Wu F, Newman B, Yoon M, Fang L, Zhao L, Gobburu JVS. Li S, et al. AAPS J. 2024 Apr 26;26(3):56. doi: 10.1208/s12248-024-00913-x. AAPS J. 2024. PMID: 38671158 Clinical Trial.
Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a combination of fluticasone propionate (FP) and salmeterol xinafoate (SX). However, the pharmacokinetics (PK) batch-to …
Advair Diskus is an essential treatment for asthma and chronic obstructive pulmonary disease. It is a dry powder inhaler with a co …
Reducing asthma treatment.
Black PN. Black PN. N Engl J Med. 2007 Aug 2;357(5):504; author reply 505-6. doi: 10.1056/NEJMc071639. N Engl J Med. 2007. PMID: 17671261 No abstract available.
2,673 results